Nothing Special   »   [go: up one dir, main page]

WO2015059714A8 - A viral vaccine and methods of manufacture thereof - Google Patents

A viral vaccine and methods of manufacture thereof Download PDF

Info

Publication number
WO2015059714A8
WO2015059714A8 PCT/IN2014/000585 IN2014000585W WO2015059714A8 WO 2015059714 A8 WO2015059714 A8 WO 2015059714A8 IN 2014000585 W IN2014000585 W IN 2014000585W WO 2015059714 A8 WO2015059714 A8 WO 2015059714A8
Authority
WO
WIPO (PCT)
Prior art keywords
manufacture
methods
virus
viral vaccine
culture
Prior art date
Application number
PCT/IN2014/000585
Other languages
French (fr)
Other versions
WO2015059714A1 (en
Inventor
Krishna Mohan Vadrevu
Venkatesan RAMASAMY
Prasanna Kumar DUVVURU
Original Assignee
Bharat Biotech International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech International Limited filed Critical Bharat Biotech International Limited
Priority to CN201480050520.1A priority Critical patent/CN105744952A/en
Priority to RU2016114285A priority patent/RU2706693C2/en
Priority to AU2014338520A priority patent/AU2014338520B2/en
Publication of WO2015059714A1 publication Critical patent/WO2015059714A1/en
Publication of WO2015059714A8 publication Critical patent/WO2015059714A8/en
Priority to PH12016500500A priority patent/PH12016500500A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides novel processes and appropriate experimental techniques which would maximize antigen yield, and also stabilize Vero-cell derived purified inactivated Japanese encephalitis virus bulk. Alternative methods of cell culture and virus culture are disclosed for commercial manufacture of vaccine formulations. The stabilized inactivated virus bulk can be stored for a long time at 2°C -8°C until vaccine formulation.
PCT/IN2014/000585 2013-09-14 2014-09-08 Emergency mode in a hybrid vehicle WO2015059714A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201480050520.1A CN105744952A (en) 2013-09-14 2014-09-08 A viral vaccine and methods of manufacture thereof
RU2016114285A RU2706693C2 (en) 2013-09-14 2014-09-08 Virus vaccine and methods for production thereof
AU2014338520A AU2014338520B2 (en) 2013-09-14 2014-09-08 A viral vaccine and methods of manufacture thereof
PH12016500500A PH12016500500A1 (en) 2013-09-14 2016-03-14 A viral vaccine and methods of manufacture thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4135/CHE/2013 2013-09-14
IN4336/CHE/2013 2013-09-25
IN4135CH2013 IN2013CH04135A (en) 2013-09-14 2014-09-08

Publications (2)

Publication Number Publication Date
WO2015059714A1 WO2015059714A1 (en) 2015-04-30
WO2015059714A8 true WO2015059714A8 (en) 2015-06-18

Family

ID=52997726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000585 WO2015059714A1 (en) 2013-09-14 2014-09-08 Emergency mode in a hybrid vehicle

Country Status (6)

Country Link
CN (1) CN105744952A (en)
AU (1) AU2014338520B2 (en)
IN (1) IN2013CH04135A (en)
PH (1) PH12016500500A1 (en)
RU (1) RU2706693C2 (en)
WO (1) WO2015059714A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11162880B2 (en) 2015-11-09 2021-11-02 University Of Notre Dame Du Lac Particle size purification method and devices
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
CN111511395B (en) 2017-11-03 2024-10-15 武田疫苗股份有限公司 Methods for inactivating Zika virus and for determining completeness of inactivation
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
EP3581646A1 (en) * 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
CN111394321A (en) * 2020-03-30 2020-07-10 无锡加莱克色谱科技有限公司 Ultra-large pore size chromatography medium for virus particle purification and application method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309650B1 (en) * 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
CN102100910B (en) * 2009-12-21 2013-01-23 北京清大天一科技有限公司 Method for producing viral vaccines
CN103228293A (en) * 2010-11-30 2013-07-31 巴拉特生物技术国际有限公司 Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
US9580692B2 (en) * 2012-02-29 2017-02-28 Ge Healthcare Bioprocess R&D Ab Method for endotoxin removal

Also Published As

Publication number Publication date
RU2706693C2 (en) 2019-11-20
WO2015059714A1 (en) 2015-04-30
RU2016114285A3 (en) 2018-07-16
AU2014338520A1 (en) 2016-03-31
PH12016500500A1 (en) 2016-06-13
AU2014338520B2 (en) 2019-12-05
RU2016114285A (en) 2017-10-19
CN105744952A (en) 2016-07-06
IN2013CH04135A (en) 2015-08-14

Similar Documents

Publication Publication Date Title
WO2015059714A8 (en) A viral vaccine and methods of manufacture thereof
EP3551193A4 (en) Respiratory virus nucleic acid vaccines
HK1214509A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same (hiv)(env)
PH12018501602A1 (en) Subunit immersion vaccines for fish
WO2013110818A3 (en) Immunogens for hiv vaccination
EA201391515A1 (en) INACTIVATED DENGE VIRUS VACCINE
WO2015052543A3 (en) Malaria vaccination
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2013006569A3 (en) Herpes virus vaccine and methods of use
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EP3052518A4 (en) Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
EP3526236A4 (en) Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
PL3504225T3 (en) Novel mammalian expressed human immunodeficiency virus envelope protein antigens
MX2016014868A (en) Methods for freeze-drying and rehydrating biologics.
EP3403671A4 (en) Vaccine containing immobilized virus particles
MX2019007924A (en) Influenza vaccines.
WO2016069518A3 (en) Genetically stable replication competent sendai virus vector(s) containing and expressing optimized hiv genes
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
WO2015196180A3 (en) Influenza vaccines and methods of use thereof
WO2013029033A3 (en) Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
WO2015071763A3 (en) Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015066488A3 (en) Method for producing induced pluripotent stem cells
WO2014174532A3 (en) An improved process for the preparation of emtricitabine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14856071

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: IDP00201602154

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2014338520

Country of ref document: AU

Date of ref document: 20140908

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016114285

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 14856071

Country of ref document: EP

Kind code of ref document: A1